AST SpaceMobile (ASTS) stock underwent a massive rally today despite a lack of news from the space-based cellular broadband network company.

Cantor Fitzgerald initiated coverage of AST SpaceMobile (ASTS) with an Overweight rating and $30 price target The firm says AST’s strategic alignment with large telecom and and technology ...

AST Spacemobile, Inc. engages in the building global broadband cellular network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio.

BigBear.ai secured a government contract that sent shares soaring. AST SpaceMobile received approval from the government to begin testing its satellite broadband capabilities. New economic data ...

AST SpaceMobile announces plans to offer $400 million worth of convertible senior notes due 2032 in a private offering. The company ends its most recent quarter with $518.9 million in cash, cash ...

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Thursday reported fourth-quarter earnings of $1.5 billion. On a per-share basis, the Cambridge, Britain-based ...

The FCC has granted AST SpaceMobile Special Temporary Authorization to begin testing its satellites. AST has five BlueBird satellites in service, and will cooperate with AT&T and Verizon in the ...

MIDLAND, Texas, January 22, 2025--(BUSINESS WIRE)--AST SpaceMobile, Inc. ("AST SpaceMobile") (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network ...

AST SpaceMobile's market cap is overvalued by as much as $2 billion due to a smaller addressable market and fierce competition, justifying a sell rating. Despite promising technology and ...

Cambridge-based AstraZeneca has said it could face fines in China (Lynne Cameron/PA) Drugmaker AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it ...

In this article, we are going to take a look at where AST SpaceMobile, Inc. (NASDAQ:ASTS) stands against the other stocks. Wall Street’s main indices kicked off the trading week soaring on ...

A Conservative former minister has branded Labour's collapse of a £450million vaccine plant deal as a "terrible failure of negotiation” by the Government. Pharmaceutical company AstraZeneca ...